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Cancer cells hijack BCL-2 family survival proteins to
suppress the death effectors and thereby enforce an
immortal state. This is accomplished biochemically
by an antiapoptotic surface groove that neutralizes
the proapoptotic BH3 a helix of death proteins.
Antiapoptotic MCL-1 in particular has emerged as
a ubiquitous resistance factor in cancer. Although
targeting the BCL-2 antiapoptotic subclass effec-
tively restores the death pathway in BCL-2-depen-
dent cancer, the development of molecules tailored
to the binding specificity of MCL-1 has lagged. We
previously discovered that a hydrocarbon-stapled
MCL-1 BH3 helix is an exquisitely selective MCL-1
antagonist. By deploying this unique reagent in a
competitive screen, we identified an MCL-1 inhibitor
molecule that selectively targets the BH3-binding
groove of MCL-1, neutralizes its biochemical lock-
hold on apoptosis, and induces caspase activation
and leukemia cell death in the specific context of
MCL-1 dependence.
INTRODUCTION
BCL-2 is the founding member of a family of anti- and
proapoptotic proteins that form an interaction network to
regulate the critical homeostatic balance between cellular life
and death (Llambi and Green, 2011; Youle and Strasser,
2008). The original discovery of BCL-2 at the t(14;18) chromo-
somal breakpoint of follicular lymphoma expanded the para-
digm for cancer pathogenesis to include the inability to
undergo programmed cell death (Tsujimoto et al., 1984, 1985;
Vaux et al., 1988). The pathologic overexpression of antiapop-
totic BCL-2 and its functional homologs, such as BCL-XL and
MCL-1, has emerged as a causative mechanism for the devel-
opment, maintenance, and chemoresistance of many human
cancers (Frenzel et al., 2009; Kang and Reynolds, 2009). As
such, these proteins are high priority targets for therapeutic
development.Chemistry & Biology 19, 1175–118The antiapoptotic proteins contain a surface groove that can
bind and sequester—with differential potency and specificity—
the BH3 death domains of proapoptotic members (Chen et al.,
2005; Sattler et al., 1997). BH3-only proapoptotics, such as
BID and BIM, contain a single BH3 domain and function as
afferent sensors of cellular stress, delivering their deathmessage
to the ‘‘multidomain’’ anti- and proapoptotic members, which
regulate the cellular life-death decision at the level of the mito-
chondrion (Shamas-Din et al., 2011). When activated directly
by BH3-only interaction and/or indirectly by BH3-only-mediated
competitive displacement from antiapoptotics, the multidomain
proapoptotic proteins BAX and BAK undergo a monomer-to-
oligomer transformation that results in outer mitochondrial
membrane poration and release of apoptogenic factors (Walen-
sky and Gavathiotis, 2011). Although cancer cells deploy the
antiapoptotic proteins to silence this proapoptotic pathway,
pharmacologic antagonists of antiapoptotic proteins hold
promise to restore the death pathway in cancer. Thus, a series
of small molecule screens and structure-based methodologies
were initially applied to target BCL-2, yielding an eclectic array
of small molecules and peptides with various degrees of bio-
chemical, cellular, and in vivo activity (Degterev et al., 2001;
Enyedy et al., 2001; Kitada et al., 2003; Nguyen et al., 2007;
Oltersdorf et al., 2005; Petros et al., 2010; Tzung et al., 2001;
Walensky et al., 2004; Wang et al., 2000, 2006). The break-
through molecule ABT-263 is an orally bioavailable and selective
BCL-2/BCL-XL inhibitor, which is advancing through the clinical
trials process, manifesting both safety and preliminary efficacy in
BCL-2-dependent cancers (Gandhi et al., 2011; Roberts et al.,
2012; Tse et al., 2008; Wilson et al., 2010).
Broad experimentation with the ABT-263 molecule and its
progenitor ABT-737 revealed that expression of antiapoptotic
proteins lying outside their binding spectra caused resistance
(Konopleva et al., 2006; Lin et al., 2007; van Delft et al., 2006;
Yecies et al., 2010), compelling the development of alternative
or complementary agents that would either harbor broader anti-
apoptotic targeting capacity or inherent selectivity for antiapop-
totics like MCL-1 that evade ABT-263/737 antagonism. The
small molecule obatoclax (Nguyen et al., 2007) and the peptidic
stabilized a helix of BCL-2 domains (SAHBs) modeled after the
BID and BIM BH3 domains (Gavathiotis et al., 2008; LaBelle
et al., 2012; Walensky et al., 2004, 2006) are examples of novel
agents that more broadly target the BCL-2 family antiapoptotic6, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1175
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Figure 1. Identification of a Selective Small Molecule Inhibitor of Antiapoptotic MCL-1 by Use of a Stapled Peptide-Based Screen
(A) A high-throughput competitive fluorescence polarization (FP) binding assay was developed on the basis of the direct binding interaction between FITC-MCL-1
SAHBA and MCL-1DNDC (EC50, 14 nM) and was validated for screening using a positive control for complete displacement (BID SAHBA) and a negative control
for no displacement (BCL-2 SAHBA), yielding an assay Z-factor of 0.62. Data are mean ± SEM for FP assays performed in at least duplicate and then repeated
twice with independent MCL-1DNDC protein preparations with similar results.
(B) To enrich for MCL-1-selective small molecules, a counterscreen was developed on the basis of the direct binding interaction between FITC-BAD BH3 and
BCL-XLDC (EC50, 26 nM) and was validated for screening using a positive control for complete displacement (BAD SAHBA) and a negative control for no
displacement (MCL-1 SAHBA), yielding an assay Z-factor of 0.71. Data aremean ± SEM for FP assays performed in at least duplicate and then repeated twicewith
independent BCL-XLDC protein preparations with similar results.
Chemistry & Biology
Selective Targeting of Antiapoptotic MCL-1
1176 Chemistry & Biology 19, 1175–1186, September 21, 2012 ª2012 Elsevier Ltd All rights reserved
Chemistry & Biology
Selective Targeting of Antiapoptotic MCL-1proteins. Given the emergence of MCL-1 as a ‘‘top ten’’ patho-
logic factor across the diversity of human cancers (Beroukhim
et al., 2010), elucidating the blueprint for selective MCL-1 inhibi-
tion has also become a major focus of academic and pharma-
ceutical researchers.
We recently generated a library of SAHBs modeled after
the diversity of natural BH3 domains and discovered that the
BH3 helix of MCL-1 was itself the most potent and selective
natural BH3 inhibitor of MCL-1 (Stewart et al., 2010). Although
the unmodifiedMCL-1 BH3 peptide was predominantly unstruc-
tured and showed little MCL-1 binding activity, we sought to
determine whether the structurally fortified and MCL-1-selective
stapled peptide could be deployed in a competitive binding
screen to, in turn, identify a selective small molecule antagonist
for reactivating apoptosis in MCL-1-dependent cancer. Thus, in
addition to serving as a novel class of therapeutics in their own
right, the development and application of high-affinity, high-
selectivity stapled peptides for competitive screening could
likewise be an effective and generalizable strategy for small
molecule drug discovery.
RESULTS
From Selective Stapled Peptide to Selective Small
Molecule
MCL-1 SAHBs are hydrocarbon-stapledMCL-1 BH3 helices that
were previously shown using chemical, structural, and biological
methods to selectively target MCL-1 and sensitize cancer cells
to caspase-dependent apoptosis (Stewart et al., 2010). Here,
we deployed MCL-1 SAHBA as a high-fidelity screening tool to
determine whether its potency and specificity-of-action could
be harnessed for small molecule discovery. A high-throughput
competitive fluorescence polarization (FP) screening assay (Z-
factor, 0.62) was developed on the basis of the direct binding
interaction between FITC-MCL-1 SAHBA and MCL-1DNDC
(EC50, 14 nM) (Figure 1A; Figure S1A available online). A compi-
lation of 71,296 small moleculeswas screened for the capacity to
displace FITC-MCL-1 SAHBA from recombinant MCL-1DNDC
(aa 172–327). To enrich for MCL-1-selective molecules by de-
tecting binding activity for the BCL-XL subclass of antiapoptotic
proteins, the library was also counterscreened using a competi-
tive FP assay (Z-factor, 0.71) developed on the basis of the direct
and selective interaction between FITC-BAD BH3 and BCL-
XLDC (EC50, 26 nM) (Figure 1B). Small molecules with an
apparent preference for MCL-1DNDC (208 compounds, 0.3%
hit rate), as defined both by >50% displacement of the FITC-(C) Based on the results of the primary screen, 208 molecules were subjected to
the selection criteria (yellow shading) of >50% displacement of the FITC-MCL
displacement from MCL-1DNDC versus BCL-XLDC (right).
(D) The 130 identified compounds were then tested in a second differential binding
of >50% displacement of the FITC-BID BH3/MCL-1DNDC interaction (left) and a >
(right).
(E) Dose-responsive competitive binding against the FITC-MCL-1 SAHBA/MCL-
shading).
(F) The identified MCL-1-selective molecules fell into discrete structural classes,
(G) MIM1 was chosen as the lead MCL-1-selective small molecule inhibitor on the
biological properties profile. The molecular structure of MIM1 is characterized b
R groups.
See also Figure S1.
Chemistry & Biology 19, 1175–118MCL-1 SAHBA/MCL-1DNDC interaction and a >45% difference
in peptide displacement from MCL-1DNDC versus BCL-XLDC,
were advanced to increasingly stringent confirmatory in vitro
binding assays, including the following: (1) repeat single-dose
testing of 208molecules in the differential competitive FP screen
(Figure 1C); (2) alternative single-dose selectivity screen for 130
confirmed MCL-1-directed antagonists comparing relative dis-
placement of FITC-BID BH3, a dual binder (Zhai et al., 2006),
from MCL-1DNDC versus BCL-XLDC (Figure 1D); and then (3)
dose-responsive competitive binding of the 64 most selective
molecules against the FITC-MCL-1 SAHBA/MCL-1DNDC com-
plex (Figure 1E). Of the 64 compounds that competed with
FITC-MCL-1 SAHBA for MCL-1DNDC binding at IC50 potencies
of <30 mM, many of which fell into discrete structural classes
(Figure 1F), 28 small molecules were subjected to dose-respon-
sive target selectivity analysis in the comparative FITC-BID BH3/
MCL-1DNDC versus FITC-BID BH3/BCL-XLDC competition FP
assay (Figure S1B), and then to screening liposomal release
and Bax/Bak/ mouse embryonic fibroblast (MEF) cytotox-
icity assays. Ultimately, we selected 4-((E)-(((Z)-2-(cyclohexyli-
mino)-4-methylthiazol-3(2H)-yl)imino)methyl)benzene-1,2,3-triol
(Figure 1G; Figure S1C), termed MCL-1 Inhibitor Molecule 1
(MIM1), as our prototype compound because of a combination
of favorable biophysical and biological properties that included
MW >200, solubility, stability (Figure S1D), nonreactivity, MCL-1
binding potency and selectivity, compatibility with and activity in
a BAX-mediated liposomal release assay, and relatively little to
no toxicity in Bax/Bak/ MEFs.
The molecular structure of MIM1 (MW 347) is characterized
by a thiazolyl core substituted with methyl, cyclohexylimino,
and benzenetriol R groups (Figure 1G). Preliminary SAR analysis
revealed the preference for a methyl and cyclic group
combination at positions R1 or R3 of the thiazolyl core and
maintenance of all three hydroxyl substituents of the benzene-
triol moiety, although select variations on this theme were also
tolerated (Figures S1B and S2). We chose to vet the antiapop-
totic binding selectivity of MIM1 in competitive FP assays by
comparison with ABT-737, a selective BCL-2/BCL-XL inhibitor
molecule (Oltersdorf et al., 2005). Although MIM1 effectively
competed with FITC-MCL-1 SAHBA and FITC-BID BH3 for
MCL-1DNDC binding with respective IC50 values of 4.7 and
4.8 mM, the compound showed no capacity to displace FITC-
BID BH3 from BCL-XLDC (IC50 >50 mM), mirroring the selec-
tivity of MCL-1 SAHBD (Figures 2A–2C). In striking contrast,
ABT-737 competed with FITC-BID BH3 for BCL-XLDC binding,
but showed no activity toward MCL-1DNDC (Figures 2A–2C).repeat testing in the differential competitive FP screen, and 130 molecules met
-1 SAHBA/MCL-1DNDC interaction (left) and a >45% difference in peptide
selectivity screen, and 64molecules met the selection criteria (yellow shading)
45% difference in peptide displacement fromMCL-1DNDC versus BCL-XLDC
1DNDC interaction identified 28 small molecules with an IC50 <30 mM (yellow
numbered 1–8.
basis of the results of the screening algorithm and a favorable biophysical and
y a thiazolyl core substituted with methyl, cyclohexylimino, and benzenetriol
6, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1177
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Figure 2. MIM1 Displays the MCL-1 Binding Selectivity of MCL-1
SAHB and the Opposite Interaction Profile of ABT-737
(A) MCL-1 SAHBD and MIM1 dose-responsively competed with FITC-MCL-1
SAHBA for binding to MCL-1DNDC, whereas the BCL-2/BCL-XL-selective
antagonist ABT-737 had no effect.
(B) Similarly, MCL-1 SAHBD andMIM1, but not ABT-737, effectively competed
with FITC-BID BH3 peptide for binding to MCL-1DNDC.
(C) In contrast, ABT-737 dose-responsively competed with FITC-BID BH3 for
binding to BCL-XLDC, whereas MCL-1 SAHBD and MIM1 showed no BCL-
XLDC-binding activity.
Data are mean ± SEM for FP assays performed in at least duplicate and then
repeated twice with independent protein preparations with similar results. CI,
confidence intervals. See also Figure S2.
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Selective Targeting of Antiapoptotic MCL-1Although MCL-1 SAHBD was a 30–60-fold more potent compet-
itor for MCL-1DNDC binding than MIM1, the MCL-1-selective
small molecule is one-seventh the size of the stapled peptide
and exhibits an IC50 for its target (4.8 mM) that is only 7.5-fold
less than that of chemically-optimized ABT-737 for BCL-XLDC1178 Chemistry & Biology 19, 1175–1186, September 21, 2012 ª201(0.63 mM) upon competition with FITC-BID BH3. Thus, MIM1
emerged from the competitive screen with a marked MCL-
1DNDC preference that reflects the binding specificity of the
stapled peptide ligand and the opposite interaction profile of
ABT-737.
Structural Analysis of the MIM1/MCL-1DNDC
Interaction
To localize the protein interaction site that accounts for compet-
itive small molecule binding activity, we performedNMR analysis
of 15N-MCL-1DNDC upon MIM1 titration. The addition of MIM1
up to a 2:1 molecule-to-protein ratio induced significant back-
bone amide chemical shift changes in those MCL-1DNDC resi-
dues concentrated in a subregion of the canonical BH3-binding
pocket, which is composed of residues from a2 (BH3) and
portions of a3, a4, a5 (BH1), and a8 (BH2) (Figure 3A). Compar-
ison of the 15N-MCL-1DNDC chemical shift changes upon titra-
tion with MIM1 versus MCL-1 SAHBD further confirmed the
colocalization of small molecule and stapled peptide binding
interactions at the canonical BH3-binding site (Figure 3B), as
also observed for BID BH3 by NMR analysis (Liu et al., 2010).
These data are consistent with a direct interaction between
MIM1 and MCL-1DNDC at the very surface employed by BH3
helices to engage MCL-1.
We next performed molecular docking analysis to examine
the predicted interactions between MIM1 and MCL-1DNDC at
the BH3-binding pocket. Interestingly, MIM1 is predicted to
occupy that portion of the BH3-binding site engaged by residues
ETLRRV (aa 211–216) of MCL-1 SAHBD (Figures 3C and 3D)
(Stewart et al., 2010). Although the cyclohexyl group is predicted
tomake complementary hydrophobic contacts with the region of
the protein interface flanked by MCL-1 SAHBD residues L213
and V216, the thiazolyl core and its methyl substituent are pre-
dicted to point directly into a deep crevice occupied in the
MCL-1 SAHBD/MCL-1DNDC complex by the highly conserved
leucine (MCL-1 SAHBD L213) of BH3 domains. Interestingly,
the benzene-1,2,3-triol (or pyrogallol) moiety is predicted to
engage in hydrophilic contacts with D256 and R263, two
charged MCL-1 residues implicated in complementary electro-
static interactions with a variety of BH3 domain R/D pairs (e.g.,
aa R214 and D218 of MCL-1 SAHBD). Of note, several residues
predicted to interact with MIM1 on the basis of the docking
analysis are not apparent by NMR because select BH3-binding
pocket residues are unassigned (e.g., M250, V253, F254,
S255, D256, G257, G262, and R263). Single-point mutagenesis
of individual residues predicted to interact with MIM1 on the
basis of the docking analysis (M231, L235, V253, D256, and
R263) and/or that undergo prominent chemical shift change
upon MIM1 titration (M231 and L235), impaired or abrogated
FITC-MCL-1 SAHBA binding to MCL-1DNDC (Figures 4A and
4B). For the MCL-1DNDC L235A and MCL-1DNDC M231A
constructs that retain sufficient FITC-MCL-1 SAHBA binding to
permit competitive binding analysis, both MIM1 and MCL-1
SAHBD manifested a similar degree of impairment in mutant
compared to wild-type MCL-1DNDC binding (Figures 4C and
4D). Taken together, these data suggest that MIM1 simulates
key molecular features of approximately 1.5 turns of the MCL-1
BH3 helix at a potential selectivity hotspot on the MCL-1 binding
surface.2 Elsevier Ltd All rights reserved
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(B) Measured chemical shift changes of 15N-MCL-1DNDC upon MCL-1 SAHBD titration up to a ratio of 2:1 MCL-1 SAHBD:MCL-1DNDC are plotted as a function
of MCL-1DNDC residue. Affected residues are represented as green bars in the plot (calculated significance threshold >0.14 ppm) and predominantly localize to
the canonical BH3-binding pocket, which is composed of amino acids from a2 (BH3) and portions of a3, a4, a5 (BH1), and a8 (BH2). Of note, the plot does not
reflect all MCL-1 SAHBD-induced changes within the canonical pocket because select residues could not be assigned as a result of large chemical shift changes
or were not previously assigned in the unliganded structure (see above).
(C and D) The docked structure of MIM1 at the canonical BH3-binding pocket of MCL-1DNDC predicts that (1) the cyclohexyl group makes complementary
hydrophobic contacts with the region of the protein interface flanked by MCL-1 SAHBD residues L213 and V216, (2) the thiazolyl core and its methyl substituent
point directly into a deep crevice occupied by MCL-1 SAHBD L213 in the stapled peptide/protein complex, and (3) the benzene-1,2,3-triol (or pyrogallol) moiety
engages in hydrophilic contacts with D256 and R263, two chargedMCL-1 residues implicated in complementary electrostatic interactionswith R214 and D218 of
MCL-1 SAHBD.
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Selective Targeting of Antiapoptotic MCL-1MIM1 Blocks MCL-1-Mediated Suppression of
Proapoptotic BAX
We next examined whether MIM1 could selectively block
MCL-1DNDC-based suppression of BAX activation, as moni-
tored by a BAX-mediated liposomal release assay tailored to
distinguish between pharmacologic regulation by MCL-1DNDC
versus BCL-XLDC. The BH3-only protein tBID directly triggers
the transformation of monomeric BAX into a membrane-
embedded oligomer that porates liposomal vesicles and re-
leases encapsulated fluorophore; the addition of antiapoptotic
proteins, such as MCL-1DNDC or BCL-XLDC, blocks tBID-
induced BAX activation and liposomal release (Figure 5A).
Although the BAX-suppressive effects of MCL-1DNDC were
completely eliminated by preincubation with MCL-1 SAHBD,
BCL-XLDC-based inhibition of BAX activation was unimpeded
by the MCL-1-selective stapled peptide (Figure 5B). Conversely,
ABT-737, which selectively blocks BCL-XLDC, negated BCL-
XLDC-mediated suppression of BAX activation but had no effect
on MCL-1DNDC activity (Figure 5C). Having documented the
high fidelity of this tailored liposomal assay for distinguishingChemistry & Biology 19, 1175–118between antiapoptotic selectivities, we next evaluated the func-
tional activity of MIM1. Indeed, we found that MIM1 simulates
the pharmacologic activity of MCL-1 SAHBD, preventing BAX
suppression by MCL-1DNDC but not by BCL-XLDC (Figure 5D).
Consistent with the reduced molecular weight and competitive
binding activity of MIM1 compared to MCL-1 SAHBD, the
kinetics of MIM1 inhibition of MCL-1DNDC-mediated BAX sup-
pression were correspondingly slower (Figures 2A, 2B, 5B, and
5D). Thus, these data explicitly link the selective MCL-1DNDC
binding activity of MIM1 with functional blockade of MCL-
1DNDC-mediated inhibition of BAX activation.
Selective Activation of MCL-1-Dependent Leukemia
Cell Death by MIM1
One of the key challenges in developing and applying molecular
antagonists for BCL-2 family antiapoptotic proteins is the vari-
able expression of multiple homologs. That is, a cancer cell will
be susceptible to a selective antiapoptotic inhibitor only if the
cell is especially dependent on that particular survival protein.
Thus, the mere expression of MCL-1 does not predict cancer6, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1179
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Figure 4. Point Mutagenesis of Discrete
Residues within the BH3-Binding Groove
of MCL-1DNDC Disrupts Interaction with
MCL-1 SAHB and MIM1
(A) A series of MCL-1DNDC residues predicted to
interact with MIM1 on the basis of the docking
and/or NMR analyses, including M231, L235,
V253, D256, and R263, weremutated to alanine for
comparative FP binding studies.
(B) Compared to wild-type MCL-1DNDC, alanine
mutagenesis of the indicated residues impaired
or abrogated FITC-MCL-1 SAHBA binding. The
dotted line indicates the mP and corresponding
dosing levels used for MCL-1DNDC, MCL-1DNDC
L235A, and MCL-1DNDC M231A in the competi-
tive FP assays below.
(C and D) MIM1 and MCL-1 SAHBD manifest
a similar degree of impairment in binding to
mutant versus wild-type protein for the MCL-
1DNDC L235A and MCL-1DNDC M231A con-
structs, which retained sufficient FITC-MCL-1
SAHBA binding (B) to enable competitive binding
analyses.
Data are mean ± SEM for FP assays performed in
at least duplicate and then repeated twice with
independent protein preparations with similar
results.
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Selective Targeting of Antiapoptotic MCL-1cell sensitivity to an MCL-1-selective inhibitor, because other
antiapoptotics lying outside its binding spectrum may con-
tinue to effectively suppress BAX/BAK. To test MIM1’s activity
and specificity in cancer cells, we employed murine BCR-
ABL(p185)-transformed, Arf null, B-lineage acute lymphoblastic
leukemia (p185+Arf/ B-ALL) cells that are unable to survive
upon Mcl-1 deletion unless reconstituted with MCL-1 or BCL-
XL, reflecting a stringent system for assessing MCL-1 and
BCL-XL dependence. To validate the cellular assay, we first
compared the effect of ABT-737 on p185+Arf//Mcl-1-deleted
B-ALL cells rescued by overexpression ofMCL-1 or BCL-XL (Fig-
ure S3A) and observed dose-responsive impairment of cancer
cell viability (IC50, 1.6 mM) that coincided with dose-responsive
caspase 3/7 activation in the BCL-XL-dependent cells, but no
effect on the MCL-1-dependent cells (Figure 6A). Strikingly,
MIM1 had the exact opposite effect, negatively impacting the
viability of the MCL-1-dependent cells (IC50, 4.2 mM), including
dose-dependent induction of caspase 3/7 activity, but having
little to no effect on the BCL-XL-dependent cells (Figure 6B).
MIM1’s cytotoxic effect on the MCL-1-dependent cells likewise
corresponded to dose-dependent dissociation of the inhibitory
MCL-1/BAK complex, as assessed by coimmunoprecipitation
analysis (Figure S3B). Importantly, ABT-737 and MIM1 had no
significant effect on the viability of wild-type or Bax/Bak/
MEFs over the same dose range, with no observed caspase
3/7 activation (Figures S3C and S3D).
We next examined the functional impact of combining ABT-
737 and MIM1 in isogenic p185+Arf/ B-ALL cells differing
only in their expression of MCL-1 and BCL-XL (Figure S3A). In
parental p185+Arf/ B-ALL cells that express both endogenous
MCL-1 and BCL-XL, the combination of ABT-737 (IC50, 5.1 mM)
and MIM1 (IC50, 10.6 mM) resulted in synergistic cytotoxicity,
as determined by CalcuSyn analysis (Chou, 2006) (IC50,
1.4 mM; CI at ED50, 0.47) (Figure 6C). Of note, MIM1, like ABT-1180 Chemistry & Biology 19, 1175–1186, September 21, 2012 ª201737, was somewhat more active in the rescued compared to
the parental cell line, consistent with the presence of increased
levels of displaceable BH3-only proteins, such as BIM, in
complex with overexpressed antiapoptotic protein (Figure S3E)
(Certo et al., 2006; Del Gaizo Moore et al., 2007; Merino
et al., 2012). Strikingly, when the MIM1/ABT-737 combination
was applied to MCL-1-reconstituted p185+Arf//Mcl-1-deleted
B-ALL cells, the addition of ABT-737 had little effect (Figure 6D).
Similarly, the cytotoxic effects of single agent ABT-737 and
the combination on BCL-XL-reconstituted p185
+Arf//Mcl-1-
deleted B-ALL cells were identical, reflecting no added benefit
of MIM1 in the absence of MCL-1 (Figure 6E). These data under-
score the selectivity of MIM1 and ABT-737 for their respective
targets in the context of high-stringency cancer cell dependence
on MCL-1 or BCL-XL. The relative resistance of nonmalignant,
wild-type fibroblasts to MIM1 treatment (Figure S3C), as ob-
served for ABT-737 (Figure S3D) (van Delft et al., 2006), suggests
that a therapeutic window may exist, with preferential toxicity to
cells driven by discrete antiapoptotic blockades.
DISCUSSION
Cancer cells are empowered by a combination of proliferative
drive and apoptotic blockade. Under homeostatic conditions,
BCL-2 family antiapoptotic proteins guard against premature or
unwanted cellular death, but in the context of cancer, their over-
expression subverts the natural death pathway and promotes
tumor development,maintenance, recurrence, and chemoresist-
ance. To reduce the apoptotic threshold in cancer and thereby
facilitate the efficacy of chemotherapy and radiation treatment,
an ideal arsenal of targeted apoptotic therapies would include
agents with specificities tailored to individual, subsets of, and
all antiapoptotic proteins. The BH3 helix-binding groove on the
surface of antiapoptotic proteins represents the pharmacologic2 Elsevier Ltd All rights reserved
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Figure 5. Selective Blockade of MCL-1-
Mediated Suppression of BAX Activation
by MIM1
(A) BH3-only protein tBID directly activates BAX-
mediated liposomal release, which is effectively
suppressed by treatment with antiapoptotic MCL-
1DNDC and BCL-XLDC.
(B) MCL-1 SAHBD selectively inhibited MCL-
1DNDC suppression of tBID-induced BAX acti-
vation.
(C) ABT-737 selectively inhibited BCL-XLDC
suppression of tBID-induced BAX activation.
(D) The activity profile of MIM1 in the liposomal
release assay mirrored the MCL-1 selectivity of
MCL-1 SAHBD.
Liposomal assays were conducted in triplicate
for each condition and repeated with an indepen-
dent preparation of recombinant BAX with similar
results.
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Selective Targeting of Antiapoptotic MCL-1bull’s-eye for such targeted therapies. The first structure of a
proapoptotic BH3 helix in complex with antiapoptotic BCL-XL
(Sattler et al., 1997) provided the blueprint for developing such
molecules and designer peptides. The bench-to-bedside find-
ings from ABT-737 and ABT-263 have yielded enormous insight
into the remarkable potential and remaining challenges of this
pharmacologic strategy. Deciphering the topographic hot spots
that dictate similarities and differences among the BH3-binding
sites of numerous antiapoptotic proteins presents a considerable
drug design challenge. However, the advancement of ABT-263,
and a growing diversity of small molecules and peptides that
address the variety of BCL-2 family targets (Arnold et al., 2008;
Doi et al., 2012; Feng et al., 2010; Kazi et al., 2011; LaBelle
et al., 2012; Lee et al., 2008; Boersma et al., 2012; Mohammad
et al., 2007; Nguyen et al., 2007; Oh et al., 2010; Paoluzzi et al.,
2008; Petros et al., 2010; Placzek et al., 2011; Stewart et al.,
2010; Wang et al., 2006; Zhang et al., 2011; Zheng et al., 2012),
predicts that this pharmacologic puzzle can ultimately be solved.
With BCL-2/BCL-XL-selective inhibitors having led the field,
significant attention has shifted to expanding the scope of anti-
apoptotic targeting, with a special emphasis onMCL-1, a ubiqui-
tous pathogenic and resistance factor in cancer. To uncover the
binding and specificity determinants for MCL-1, we generated a
library of hydrocarbon-stapled BH3 helices to screen for a natu-
rally selective MCL-1 inhibitor. Ironically, the BH3 helix of MCL-1
itself emerged as the most potent and selective antagonist.
Biochemical and structural analysis of the MCL-1 SAHBD/Chemistry & Biology 19, 1175–1186, September 21, 2012 ªMCL-1DNDC interaction provided new
insight into key distinguishing features of
the binding interface and how they could
potentially be harnessed for drug devel-
opment (Stewart et al., 2010). Here, we
applied this uniquely selective, high-
affinity stapled peptide to screen for small
molecules that could effectively displace
it from the BH3-binding groove of MCL-
1DNDC, yet not target BCL-XL. MIM1
emerged as a potent and selective
small molecule inhibitor of MCL-1DNDC,capable of targeting the canonical BH3-binding pocket of
MCL-1, blocking MCL-1-mediated suppression of tBID-induced
BAX activation in vitro, and inducing caspase 3/7 activation and
cell death in MCL-1-dependent, but not BCL-XL-dependent,
leukemia cells. In each case, ABT-737 had the opposite bio-
chemical and cellular activity profile of MIM1, and synergized
withMIM1 only in the context of dual MCL-1 and BCL-XL expres-
sion. These data indicate that MIM1may serve as a prototype for
the development of next generation small molecules that effec-
tively reduce the apoptotic threshold in cancers specifically
driven by antiapoptotic MCL-1.
SIGNIFICANCE
Targeted inhibition of the BCL-2/BCL-XL subclass of antia-
poptotic proteins is a clinically validated approach to over-
coming the survival advantage of select cancers driven by
BCL-2/BCL-XL-mediated apoptotic blockade. The emerging
pathogenic role of MCL-1 in a remarkably broad range of
human cancers has catapulted its importance as a high-
priority therapeutic target. Harnessing the potency and
selectivity of a natural MCL-1 antagonist, the BH3 domain
of MCL-1 itself, we conducted a competitive small molecule
screen against a high-affinity stapled peptide/protein com-
plex. Applying a series of rigorous biochemical and cellular
assays designed to vet MCL-1 versus BCL-XL antiapoptotic
subclass specificity, we validated MIM1 as a potent and2012 Elsevier Ltd All rights reserved 1181
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Figure 6. MCL-1-Dependent Antileukemia
Activity of MIM1 and Synergy with ABT-737
(A) ABT-737 selectively impaired the viability of
p185+Arf/Mcl-1-deleted B-ALL cells rescued by
BCL-XL, but not MCL-1, as measured by CellTiter-
Glo assay at 24 hr. The selective cytotoxic effect of
ABT-737 was accompanied by dose-responsive
caspase 3/7 activation in the BCL-XL-rescued
leukemia cell line, as measured at 8 hr after
treatment.
(B) MIM1 exhibited the opposite cellular activity
profile of ABT-737, selectively impairing the
viability of p185+Arf/Mcl-1-deleted B-ALL cells
rescued by MCL-1, but not BCL-XL. Correspond-
ingly, the selective cytotoxic effect of MIM1 was
accompanied by dose-responsive caspase 3/7
activation only in the MCL-1-rescued leukemia
cell line.
(C) Combination treatment with MIM1 and
ABT-737 induced synergistic killing of parental
p185+Arf/ B-ALL cells that express endogenous
MCL-1 and BCL-XL, as reflected by a leftward shift
of the viability isotherm (left) and the CalcuSyn
dose effect curve (right), with calculated CI values
of <1 at ED50, ED75, and ED90. CI, combination
index; ED, effective dose.
(D) The addition of ABT-737 to MIM1 treatment of
MCL-1-rescued p185+Arf/Mcl-1-deleted B-ALL
cells had little to no additional cytotoxic effect,
consistent with the relative inactivity of ABT-737 in
the context of MCL-1-dependence.
(E) Correspondingly, the addition of MIM1 to
ABT-737 treatment of BCL-XL-rescued p185
+
Arf/Mcl-1-deleted B-ALL cells provided no
additional cytotoxic effect, consistent with the
relative inactivity of MIM1 in the context of BCL-
XL-dependence.
Data are mean ± SEM for experiments performed
in at least duplicate, normalized to vehicle control,
and repeated twice with independent cell cultures
with similar results. See also Figure S3.
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Selective Targeting of Antiapoptotic MCL-1selective MCL-1 antagonist capable of preferentially block-
ing MCL-1-mediated suppression of proapoptotic BAX
in vitro, and inducing caspase 3/7 activation and cell death
of a strictly MCL-1-dependent leukemia. Thus, we find that
high-fidelity targeting of MCL-1 by a small molecule is
achievable and can be combined with selective BCL-2/
BCL-XL inhibition to exert synergistic anticancer activity.1182 Chemistry & Biology 19, 1175–1186, September 21, 2012 ª2012 Elsevier Ltd All rights rEXPERIMENTAL PROCEDURES
SAHB Synthesis
Hydrocarbon-stapled peptides corresponding to
BCL-2 family BH3 domains and their FITC-bAla
derivativeswere synthesized, purified, and charac-
terized according to previously describedmethods
(Bird et al., 2008; Walensky et al., 2004, 2006). The
sequence compositions of BH3 peptides used
in this study are indicated in Figure S1A.
BCL-2 Family Protein Production
Recombinant MCL-1DNDC, BCL-XLDC, and full-
length BAX were expressed and purified as
previously reported (Gavathiotis et al., 2008; Pitter
et al., 2008). Point mutations in MCL-1DNDC weregenerated by PCR-based site-directed mutagenesis (QuikChange Mutagen-
esis Kit, Stratagene) followed by DNA sequencing to verify the constructs.
Transformed Escherichia coli BL21 (DE3) were cultured in ampicillin-contain-
ing Luria Broth, and protein expression was induced with 0.5 mM isopropyl
b-D-1-thiogalactopyranoside (IPTG). The bacterial pellets were resuspended
in buffer (1% Triton X-100 in PBS, complete protease inhibitor tablet for
MCL-1DNDC and BCL- XLDC, and 250 mM NaCl, 20 mM Tris, and complete
protease inhibitor tablet [pH 7.2] for BAX), sonicated, and after centifugationeserved
Chemistry & Biology
Selective Targeting of Antiapoptotic MCL-1at 45,0003 g for 45 min, the supernatants were applied to glutathione-sephar-
ose columns (GE Healthcare) for GST-MCL-1DNDC and BCL-XLDC, or a chitin
column (BioLabs) for Intein-BAX. On-bead digestion of GST-tagged protein
was accomplished by overnight incubation at room temperature in the pres-
ence of thrombin (75 units) in PBS (3 ml), whereas the intein tag was cleaved
from BAX by overnight incubation of the chitin beads at 4C with 50 mM
DTT. The tagless recombinant proteins were purified by size exclusion chro-
matography (SEC) using a Superdex-75 column (GE Healthcare) with
150 mM NaCl and 50 mM Tris (pH 7.4) buffer conditions for MCL-1DNDC
and BCL-XLDC, and 20 mM HEPES (pH 7.2), 150 mM KCl buffer conditions
for full-length monomeric BAX protein.
Fluorescence Polarization Binding Assays
Fluorescence polarization (FP) assays were performed as previously
described (Bernal et al., 2010; Pitter et al., 2008). Briefly, direct binding curves
were first generated by incubating FITC-MCL-1 SAHBA, FITC-BID BH3, or
FITC-BAD BH3 (15 nM) with serial dilutions of antiapoptotic protein, and FP
was measured at 5 min on a SpectraMax M5 microplate reader (Molecular
Devices). For competition assays, a serial dilution of small molecule or acety-
lated peptide was added to recombinant protein at EC75 concentration, as
determined by the direct binding assay (e.g., FITC-BID BH3: MCL-1DNDC,
45 nM; BCL-XLDC, 300 nM). FP was measured at equilibrium, and IC50 values
were calculated by nonlinear regression analysis of competitive binding curves
using Prism software (GraphPad).
High-Throughput Screening
Small molecule screening was performed at the Institute for Chemistry
and Cellular Biology (ICCB) of Harvard Medical School, utilizing the commer-
cial libraries Asinex1 (12,378 molecules), Chembridge3 (10,560 molecules),
ChemDiv4 (14,677 molecules), Enamine2 (26,576), Life Chemicals1 (3,893
molecules), and Maybridge5 (3,212 molecules). High-throughput competitive
FP binding assays were employed to screen for small molecules that disrupted
the FITC-MCL-1 SAHBA/MCL-1DNDC, but not the FITC-BADBH3/BCL-XLDC,
interaction. SEC-purified MCL-1DNDC or BCL-XLDC (see above) was deliv-
ered by automated liquid handler (WellMate, Matrix) to 384 well plates, fol-
lowed by the addition of small molecule libraries (5 mg/ml, 100 nl). After a
15 min incubation at room temperature, the corresponding FITC-SAHB
(15 nM) was added to each well by liquid handler and FP read at 1 hr using
a PerkinElmer Envision plate reader (lex 480 nm, lem 535 nm).
MIM1 Characterization by Mass Spectrometry and 1H-NMR
Spectroscopy
4-((E)-(((Z)-2-(cyclohexylimino)-4-methylthiazol-3(2H)-yl)imino)methyl)benzene-
1,2,3-triol. LC-MS: 348(M+1,ES+); 346(M-1, ES-). 1H NMR (300 MHz, DMSO-
d6): d 11.35 (s, 1H,OH); 9.3 (s, 1H,OH); 8.42 (s, 1H,OH); 8.31(s, 1H); 6.73
(d, 1H, J = 8.4 Hz); 6.34(d, 1H, J = 8.4 Hz); 6.01(s, 1H); 3.09-3.05 (m, 1H); 2.15
(s, 3H); 1.81-1.60 (m, 5H); 1.40-1.2 (m, 3H), 1.15 (t, 2H).
NMR Samples and Spectroscopy
Uniformly 15N-labeled MCL-1DNDC was generated by modifying its expres-
sion and purification scheme in accordance with the method for producing
15N-BAX (Gavathiotis et al., 2008). Protein samples were prepared in a
20 mM HEPES and 5 mM DTT solution at pH 6.5 in 5% D2O. MIM1 (20 mM
stock) and MCL-1 SAHBD (5 mM stock) in DMSO were titrated into a solution
of 100 mM MCL-1DNDC to achieve the indicated molar ratio concentrations.
Correlation 1H-15N HSQC spectra (Grzesiek and Bax, 1993) were acquired
at 25C on a Bruker 800 MHz NMR spectrometer equipped with a cryo-
genic probe, processed using NMRPipe (Delaglio et al., 1995), and were
analyzed with NMRView (Johnson and Blevins, 1994). The weighted average
chemical shift difference D at the indicated molar ratio was calculated asﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
fðDHÞ2 + ðDN=5Þ2g=2
q
in p.p.m. The absence of a bar indicates no chemical
shift difference, or the presence of a proline or residue that is overlapped or not
assigned. MCL-1DNDC cross-peak assignments were applied as previously
reported (Liu et al., 2010). The significance threshold for backbone amide
chemical shift changes was calculated on the basis of the average chemical
shift across all residues plus the standard deviation, in accordance with stan-
dard methods (Marintchev et al., 2007).Chemistry & Biology 19, 1175–118Structure Modeling
Docked structures of MCL-1DNDC andMIM1 were generated usingGlide and
analyzed using PYMOL (DeLano, 2002).
Liposomal Release Assay
Liposomes were prepared, and release assays were performed as previously
described (Lovell et al., 2008; Yethon et al., 2003). Liposomal composition
reflects a mixture of the following molar percentages of lipids (Avanti Polar
Lipids): phosphatidylcholine, 48%; phosphatidylethanolamine, 28%; phos-
phatidylinositol, 10%; dioleoyl phosphatidylserine, 10%; and tetraoleoyl cardi-
olipin, 4%. Aliquots of mixed lipids (1 mg total) are stored in glass at 20C
under nitrogen, and before use, are resuspended in liposome assay buffer
(10 mM HEPES, 200 mM KCl, and 1 mM MgCl2 [pH 7]) containing 12.5 mM
of the fluorescent dye ANTS (8-aminonaphthalene-1,3,6-trisulfonic acid,
disodium salt) and 45 mM of the quencher DPX (p-xylene-bis-pyridinium
bromide). The resulting slurry is vortexed for 10 min and freeze-thawed five
times in liquid nitrogen and a 40C water bath, respectively. The solution is
then passed through an Avanti Mini-Extruder Set (#610000) equipped with
a 100 nm filter, followed by passage through a Sepharose column (GE
Healthcare) to remove residual ANTS/DPX. The liposomes are brought up to
a volume of 3 ml to produce a final liposome stock. For the liposomal release
assay, a total volume of 30 ml is used in 384 well black flat-bottom plates
(Costar), and baseline fluorescence measurements of 8 ml liposomes are
recorded for 10 min using a Tecan Infinite M1000 (lex 355 nm, lem 520 nm).
Following the baseline read, recombinant antiapoptotic protein, with or without
preincubated small molecule or peptide, is added to the liposomes. Subse-
quently, 20 nM caspase-cleaved mouse BID (R&D systems) and 250 nM
purified recombinant monomeric BAX is added, and fluorescence measure-
ments are recorded each minute until the release measurements plateau, at
which point the liposomes are quenched with 0.2% Triton X-100 (100%
release). The percentage release of ANTS/DPX was calculated according to
the equation ([F  F0] / [F100  F0]) 3 100, where F0 and F100 are baseline
and maximal fluorescence, respectively.
Cell Viability and Caspase 3/7 Activation Assays
BCR-ABL(p185)-transformed Arf/ B-ALL cells were generated by trans-
ducing Mcl-1+/+Arf/ mouse bone marrow with BCR-ABL(p185)-IRES-Lucif-
erase vector and then removing the cells from growth factor and stromal
support (Williams et al., 2006). MCL-1- or BCL-XL-rescued p185
+Arf//Mcl-
1-deleted B-ALL cells were generated by transducing Mcl-1f/fArf/ mouse
bone marrow with p185-IRES-Luciferase. Transformed p185+Mcl-1f/fArf/
B-ALL cells were then transduced with MSCV-Puro-Mcl-1 or MSCV-Puro-
Bcl-XL and selected to produce stable clones, which were subsequently trans-
duced with MSCV-Cre-IRES-GFP to delete the endogenous Mcl-1 alleles.
B-ALL cells were maintained in RPMI 1640 (ATCC) supplemented with 10%
(v/v) FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mM MEM nones-
sential amino acids, and 50 mM b-mercaptoethanol. Mouse embryonic fibro-
blasts (MEFs) cells were maintained in DMEM high glucose (Invitrogen)
supplemented with 10% (v/v) FBS, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 2 mM L-glutamine, 50 mM HEPES, 0.1 mM MEM nonessential amino
acids, and 50 mM b-mercaptoethanol. Leukemia cells (4 3 104/well) were
seeded in 96-well opaque plates and incubated with the indicated serial dilu-
tions of vehicle (0.4%DMSO), MIM1, ABT-737, or the combination in DMEMat
37C in a final volume of 100 ml. For MEF experiments, cells (53 103/well) were
seeded in 96-well opaque plates for 24 hr and then were incubated with the
indicated serial dilutions of vehicle (0.4% DMSO), MIM1, or ABT-737. Cell
viability was assayed at 24 hr by addition of CellTiter-Glo reagent according
to the manufacturer’s protocol (Promega), and luminescence was measured
using a SpectraMax M5 microplate reader (Molecular Devices). Caspase 3/7
activation was assayed at 8 hr by addition of Caspase-Glo 3/7 reagent accord-
ing to the manufacturer’s protocol (Promega), and luminescence measured
using a SpectraMax M5 microplate reader. Synergy of the MIM1/ABT-737
combination in leukemia cells was calculated using the CalcuSyn software
package (Chou, 2006).
Immunoprecipitation Assays
MCL-1-reconstituted p185+Arf/Mcl-1-deleted B-ALL cells (5 3 106) were
incubated with vehicle or MIM1 in culture at the indicated concentrations for6, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1183
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Selective Targeting of Antiapoptotic MCL-16 hr. The cells were lysed in 50mM Tris (pH 7.4), 150 mMNaCl, 2.5 mMMgCl2,
0.5% NP40, and complete protease inhibitor tablet, followed by pelleting of
cellular debris at 14,000 g for 10 min at 4C. The supernatant was exposed
to pre-equilibrated protein A/G sepharose beads, and the precleared superna-
tant was subsequently incubated with anti-MCL-1 antibody (Rockland) over-
night at 4C, followed by the addition of protein A/G sepharose beads for
1 hr. The beads were pelleted and washed with lysis buffer three times for
10 min at 4C. The washed beads were then pelleted and heated to 90C
for 10 min in SDS loading buffer, and the eluted protein was subjected to
SDS/PAGE and western analysis using MCL-1 and BAK (anti-BAK NT, Milli-
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